Preliminary efficacy and safety results of a new macular buckle model (NPB^®) in myopic traction maculopathy.

IF 1.4 4区医学 Q3 OPHTHALMOLOGY European Journal of Ophthalmology Pub Date : 2025-01-02 DOI:10.1177/11206721241310471

Ana Rita Viana, Matteo Ripa, André Silva, Veronika Matello, Barbara Parolini

{"title":"Preliminary efficacy and safety results of a new macular buckle model (NPB®) in myopic traction maculopathy.","authors":"Ana Rita Viana, Matteo Ripa, André Silva, Veronika Matello, Barbara Parolini","doi":"10.1177/11206721241310471","DOIUrl":null,"url":null,"abstract":"Purpose: To describe the efficacy and safety outcomes of NPB® macular buckle (MB) in myopic traction maculopathy (MTM).Methods: A monocentric, prospective cohort study of the naïve eyes who underwent MB surgery, alone or combined with pars plana vitrectomy (PPV) for MTM, using the new NPB® buckle, between December 2022 and June 2024. The anatomical results, postoperative complications, and MB ease of use were analyzed as the main outcomes. Secondary outcomes included changes in best-corrected visual acuity (BCVA), axial length (AL), and intraocular pressure (IOP).Results: Forty eyes of 39 patients were included, 34 (85%) were female. MB implantation alone was performed in 32 eyes (80%) and combined surgery in 8 (20%). At the final visit, 22 eyes (56,4%) \"resolved\" and 17 (43,6%) \"improved\" their retinal status, and 26 eyes (66,7%) \"resolved\", 8 (20,5%) \"improved\" and 5 (12,8%) \"unchanged\" their foveal status. Thirteen (32,5%) had repositioning surgery mainly due to MB decentration. Early complications (month 1) included diplopia in 3 eyes (7,5%) and elevation deficit without diplopia in 2 (5,0%). Late complications (month 6) involved mild buckle exposure in 3 cases (7,5%). No cases required MB removal or additional PPV. BCVA improved from 0,61 ± 0,35 to 0,49 ± 0,38 logMAR (p = 0,013), AL changed from 31,5 ± 2,2 to 30,0 ± 2,2 mm (p < 0,001), and IOP changed from 16,0 ± 2,7 to 14,5 ± 3,3 mmHg (p = 0,013), between the baseline and the final visit.Conclusions: The new MB model is an effective and safe technique for MTM treatment as a first-line strategy, alone or in combination with PPV.","PeriodicalId":12000,"journal":{"name":"European Journal of Ophthalmology","volume":" ","pages":"11206721241310471"},"PeriodicalIF":1.4000,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/11206721241310471","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To describe the efficacy and safety outcomes of NPB^® macular buckle (MB) in myopic traction maculopathy (MTM).

Methods: A monocentric, prospective cohort study of the naïve eyes who underwent MB surgery, alone or combined with pars plana vitrectomy (PPV) for MTM, using the new NPB^® buckle, between December 2022 and June 2024. The anatomical results, postoperative complications, and MB ease of use were analyzed as the main outcomes. Secondary outcomes included changes in best-corrected visual acuity (BCVA), axial length (AL), and intraocular pressure (IOP).

Results: Forty eyes of 39 patients were included, 34 (85%) were female. MB implantation alone was performed in 32 eyes (80%) and combined surgery in 8 (20%). At the final visit, 22 eyes (56,4%) "resolved" and 17 (43,6%) "improved" their retinal status, and 26 eyes (66,7%) "resolved", 8 (20,5%) "improved" and 5 (12,8%) "unchanged" their foveal status. Thirteen (32,5%) had repositioning surgery mainly due to MB decentration. Early complications (month 1) included diplopia in 3 eyes (7,5%) and elevation deficit without diplopia in 2 (5,0%). Late complications (month 6) involved mild buckle exposure in 3 cases (7,5%). No cases required MB removal or additional PPV. BCVA improved from 0,61 ± 0,35 to 0,49 ± 0,38 logMAR (p = 0,013), AL changed from 31,5 ± 2,2 to 30,0 ± 2,2 mm (p < 0,001), and IOP changed from 16,0 ± 2,7 to 14,5 ± 3,3 mmHg (p = 0,013), between the baseline and the final visit.

Conclusions: The new MB model is an effective and safe technique for MTM treatment as a first-line strategy, alone or in combination with PPV.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

新型黄斑扣环模型（NPB®）治疗近视牵引性黄斑病变的初步疗效和安全性结果。

目的：评价NPB®黄斑扣环（MB）治疗近视牵引性黄斑病变（MTM）的疗效和安全性。方法：在2022年12月至2024年6月期间，使用新型NPB®扣环，对接受MB手术单独或联合计划部玻璃体切除术（PPV）治疗MTM的naïve眼睛进行单中心前瞻性队列研究。以解剖结果、术后并发症和MB的易用性为主要观察指标。次要结果包括最佳矫正视力（BCVA）、眼轴长度（AL）和眼内压（IOP）的变化。结果：39例患者40只眼，其中女性34只（85%）。单独行MB植入术32眼（80%），联合手术8眼（20%）。在最后一次访问时，22只眼睛（56.4%）“解决”和“17”（43.6%）“改善”了他们的视网膜状态，26只眼睛（66.7%）“已解决”，8 （20.5%）“改善”和“5”（12.8%）“不变”他们的中央凹状态。13例（32.5%）手术复位，主要原因是MB脱位。早期并发症（第1个月）包括复视3眼（7.5%）和无复视的仰角缺损2眼（5.0%）。晚期并发症（第6个月）包括3例轻度扣环暴露（7.5%）。没有病例需要切除MB或额外的PPV。基线和最后一次访问期间，BCVA从0.61±0.35 mm改善到0.49±0.38 mm (p = 0.013)， AL从31.5±2.2 mm改善到30.0±2.2 mm （p = 0.013）。结论：无论是单独治疗还是联合PPV治疗，新的MB模型都是一种有效且安全的MTM一线治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

European Journal of Ophthalmology 医学-眼科学

CiteScore

3.60

自引率

0.00%

发文量

372

审稿时长

3-8 weeks

期刊介绍： The European Journal of Ophthalmology was founded in 1991 and is issued in print bi-monthly. It publishes only peer-reviewed original research reporting clinical observations and laboratory investigations with clinical relevance focusing on new diagnostic and surgical techniques, instrument and therapy updates, results of clinical trials and research findings.